Proud to see @CULTSKIN featured in Vogue Business this week, highlighting our work at the intersection of regenerative aesthetics, GLP-1 medicine, and hair-loss innovation.
With the rise of GLP-1 medications, we’re seeing a clear clinical pattern:
Around 10% of users experience hair shedding
At CULTSKIN we’ve recorded a 31% increase in GLP-1 patients seeking non-surgical hair-restoration support
To meet this need, my team and I developed Cultscalp® — the UK’s first GLP-1-specific hair-regeneration programme, combining:
• NAD+ injectables to support follicular energy and cellular repair
• Microneedling, PolyPhil & Keralase to improve scalp blood flow
• Dual-action serums to reduce shedding + stimulate regrowth
• Lyophilised exosomes with micro anti-inflammatory markers
• A personalised, regenerative-medicine-led protocol designed for GLP-1 physiology
As GLP-1 therapies scale globally, the conversation must include proactive biological support not just weight loss outcomes. CULTSKIN will continue to lead in developing UK-first, evidence-based solutions that protect healthspan, appearance, and confidence.
Thank you to Vogue Business for spotlighting this important work.